Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
Clinical trial NCT00773838 · COMPLETED
Trial details
- NCT number
- NCT00773838
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-12-01
- Primary completion
- 2011-05-16
- Enrollment
- 143
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.